1. Musch DC, Gillespie BW, Niziol LM, et al. Factors Associated with Intraocular Pressure before and during 9 Years of Treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2008; 115(6): 927-33. [
DOI:10.1016/j.ophtha.2007.08.010]
2. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353(5): 487-97 [
DOI:10.1056/NEJMra050100]
3. Ashburn Jr FS, Goldberg I, Kass MA. Compliance with Ocular Therapy. Surv Ophthalmol 1980; 24(4): 237-48 [
DOI:10.1016/0039-6257(80)90045-4]
4. Bloch S, Rosenthal AR, Friedman L, et al. Patient Compliance in Glaucoma. Br J Ophthalmol 1977; 61(8): 531-4. [
DOI:10.1136/bjo.61.8.531]
5. Mansouri K, Iliev ME, Rohrer K, et al. Compliance and Knowledge about Glaucoma in Patients at Tertiary Glaucoma Units. Int J Ophthalmol 2011; 31(5): 369-76. [
DOI:10.1007/s10792-011-9468-2]
6. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and Adherence with Topical Glaucoma Therapy. Am J Ophthalmol 2005; 140(4): 598. [
DOI:10.1016/j.ajo.2005.04.051]
7. Kosoko O, Quigley HA, Vitale S, et al. Risk Factors for Noncompliance with Glaucoma Follow-up Visits in a Residents' Eye Clinic. Ophthalmology 1998; 105(11): 2105-11. [
DOI:10.1016/S0161-6420(98)91134-4]
8. Patel SC, Spaeth GL. Compliance in Patients Prescribed Eyedrops for Glaucoma. Ophthalmic Surg Lasers Imaging Retina 1995; 26(3): 233-6.
9. Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006; 113(3): 431-6. [
DOI:10.1016/j.ophtha.2005.10.034]
10. Busche S, Gramer E. Improved Eyedrop Administration and Compliance in Glaucoma Patients. A Clinical Study. Klin Monbl Augenheilkd 1997; 211(4): 257-62 [
DOI:10.1055/s-2008-1035132]
11. Park MH, Kang KD, Moon J, et al. Noncompliance with Glaucoma Medication in Korean Patients: a Multicenter Qualitative Study. Jpn J Ophthalmol 2013; 57(1): 47-56 [
DOI:10.1007/s10384-012-0188-6]
12. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with Ocular Hypotensive Treatment in Patients with Glaucoma or Ocular Hypertension: An Evidence-based Review. Ophthalmology 2005; 112(6): 953-61. [
DOI:10.1016/j.ophtha.2004.12.035]
13. Robin A, Grover DS. Compliance and Adherence in Glaucoma Management. Indian J Ophthalmol 2011; 59(1): 93. [
DOI:10.4103/0301-4738.73693]
14. Rajurkar K, Dubey S, Gupta PP, et al. Compliance to Topical Anti-glaucoma Medications Among Patients at a Tertiary Hospital in North India. Journal of Current Ophthalmology 2018; 30(2): 125-9. [
DOI:10.1016/j.joco.2017.09.002]
15. Schwartz GF, Quigley HA. Adherence and Persistence with Glaucoma Therapy. Surv Ophthalmol 2008; 53: 57-68. [
DOI:10.1016/j.survophthal.2008.08.002]
16. Heydari F, Shenasi A, Akbari R. The Continuation of Treatment Adherence in Patients with Glaucoma and Glaucoma Clinic Nikoukari Hospital Tabriz. Med J Tabriz Univ Med Sci 2012; 34(5): 24-7.
17. Movahedinejad T, Adib-Hajbaghery M. Adherence to Treatment in Patients with Open-angle Glaucoma and its Related factors. Electron Physician 2016; 8(9): 2954-61. [
DOI:10.19082/2954]
18. Balkrishnan R, Bond JB, Byerly WG, et al. Medication-related Predictors of Health-related Quality of Life in Glaucoma Patients Enrolled in a Medicare Health Maintenance Organization. Am J Geriatr Pharmacother 2003; 1(2): 75-81. [
DOI:10.1016/S1543-5946(03)90003-1]
19. Kline RB. Principles and Practice of Structural Equation Modeling. New York: Guilford Publications; 2015. 20.
20. Wolf EJ, Harrington KM, Clark SL, Miller MW. Sample size requirements for structural equation models an evaluation of power, bias, and solution propriety. Educ Psychol Meas 2013;73(6): 913e934. [
DOI:10.1177/0013164413495237]
21. Mahdaviaza H, Roustaei N, Masoumpour MB, et al. Psychometric Properties of the Glaucoma Quality of Life-15 Questionnaire: Use of explanatory Factor Analysis. J Curr Ophthalmol 2017; 30(3): 211-6. [
DOI:10.1016/j.joco.2017.12.005]
22. Morisky DE, Ang A, Krousel-Wood M, et al. Predictive Validity of a Medication Adherence Measure for Hypertension Control. J Clin Hypertens 2008; 10(5): 348-54. [
DOI:10.1111/j.1751-7176.2008.07572.x]
23. Ghanei Gheshlagh R, Ebadi A, Veisi Raygani AK, et al. Determining Concurrent Validity of the Morisky Medication Adherence Scale in Patients with Type 2 Diabetes. IJRN 2015; 1(3): 24-32.
24. Virani S, Rewri P, Dhar M. Difficulties with Self Instillation of Eye Drops and its Impact on Intraocular Pressure in Glaucoma Patients. J Clin Ophthalmol Res 2015; 3(2): 87-90. [
DOI:10.4103/2320-3897.156592]
25. Tripathi S, Gupta S, Arora V. SocioDemographic Determinants of Glaucoma Medications Compliance: A North Indian Cross Sectional Study. IndianJ Clin Exp Ophthalmol 2017; 3(1): 53-6.
26. Essam OA, Mousa ABA, Humaid ASS, et al. Compliance of Glaucoma Patients to Ocular Hypotensive Medications Among the Saudi Population. J Ocular Pharmacol Ther 2016; 32(1): 50-4. [
DOI:10.1089/jop.2015.0052]
27. Kim CY, Park KH, Ahn J, et al. Treatment Patterns and Medication Adherence of Patients with Glaucoma in South Korea. Br J Ophthalmol 2017; 101(6): 801-7. [
DOI:10.1136/bjophthalmol-2016-308505]
28. Pong JCF, Lai JSM, Tham CCY, et al. Compliance with Topical Antiglaucoma Medications. HKJ Opthalmol 2003; 9(1): 12-5.
29. Ahmad I, Khan BS, Rehman M. Causes of Non-Compliance in Patients with Open Angle Glaucoma. Opthalmology 2015; 13(1): 7-9.
30. Hwang DK, Liu CJ, Pu CY, et al. Persistence of Topical Glaucoma Medication: A Nationwide Population-Based Cohort Study in Taiwan. JAMA Ophthalmol 2014; 132(12): 1446-52. [
DOI:10.1001/jamaophthalmol.2014.3333]
31. Loon SC, Jin J. The Relationship Between Quality Of Life And Adherence To Medication In Glaucoma Patients In Singapore. J Glaucoma 2015; 24(5): e36-42. [
DOI:10.1097/IJG.0000000000000007]
32. Tsai JC, McClure CA, Ramos SE, et al. Compliance Barriers in Glaucoma: a Systematic Classification. J Glaucoma 2003; 12(5): 393-8. [
DOI:10.1097/00061198-200310000-00001]
33. Dimatteo MR. Variations in Patients' Adherence To Medical Recommendations: A Quantitative Review Of 50 Years Of Research. Med Care 2004; 42(2): 200-9. [
DOI:10.1097/01.mlr.0000114908.90348.f9]
34. Tsai JC. Medication Adherence in Glaucoma: Approaches for Optimizing Patient Compliance. Curr Opin Ophthalmo 2006; 17(2): 190-5.
35. Taylor SA, Galbraith SM, Mills RP. Causes of Non-compliance with Drug Regimens in Glaucoma Patients: A Qualitative Study. J Ocul Pharmacol Ther 2002; 18(5): 401-9. [
DOI:10.1089/10807680260362687]
36. Schwartz GF. Compliance and Persistency in Glaucoma Follow-Up Treatment. Curr Opin Ophthalmol 2005; 16(2): 114-21. [
DOI:10.1097/01.icu.0000156139.05323.26]
37. Shaya FT. Compliance with Medicine. Ophthalmol Clin North Am 2005; 18(4): 611-7.
38. Quek DT, Ong GT, Perera SA, et al. Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population. Arch Ophthalmol 2011; 129(5): 643-8. [
DOI:10.1001/archophthalmol.2010.345]
39. Stryker JE, Beck AD, Primo SA, et al. An Exploratory Study of Factors Influencing Glaucoma Treatment Adherence. J Glaucoma 2010; 19(1): 66-72. [
DOI:10.1097/IJG.0b013e31819c4679]
40. Skalicky S, Goldberg I. Depression And Quality Of Life In Patients With Glaucoma: A Cross-Sectional Analysis Using The Geriatric Depression Scale-15, Assessment Of Function Related To Vision, And The Glaucoma Quality Of Life-15. J Glaucoma 2008; 17(7): 54 [
DOI:10.1097/IJG.0b013e318163bdd1]
41. Skalicky SE, Goldberg I. Adherence and Persistence: The Challenges for Glaucoma Medical Therapy. Asia-Pac J Ophthalmol 2013; 2(6): 356-61. [
DOI:10.1097/APO.0000000000000023]
42. Rotchford AP, Murphy KM. Compliance with Timolol Treatment in Glaucoma. Eye 1998; 12(2):234. [
DOI:10.1038/eye.1998.56]
43. Gurwitz JH, Yeomans SM, Glynn RJ, et al. Patient Noncompliance in the Managed Care Setting: The Case of Medical Therapy for Glaucoma. Med Care 1998; 36(3): 357-69. [
DOI:10.1097/00005650-199803000-00012]
44. Wane AM, Ndiaye MR, Wade A, et al. Compliance of Medical Treatment in Primitive Glaucoma Open Angle. J Fr Ophtalmol 2003; 26(10): 1039-44.
45. Khandekar R, Shama ME, Mohammed AJ. Noncompliance with Medical Treatment Among Glaucoma Patients in Oman-a cross-Sectional Descriptive Study. Ophthalmic Epidemiol 2005; 12(5): 303-9. [
DOI:10.1080/09286580500224602]
46. Friedman DS, Okeke CO, Jampel HD, et al. Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma. Ophthalmology 2009; 116(6): 1097-105. [
DOI:10.1016/j.ophtha.2009.01.021]
47. Rossi GC, Pasinetti GM, Scudeller L, et al. Monitoring Adherence Rates in Glaucoma Patients Using the Travatan Dosing Aid. A 6- month Study Comparing Patients on Travoprost 0.004% and Patients on Travoprost 0.004%/timolol 0.5% Fixed Combination. Expert Opin Pharmacother 2010; 11(4): 499-504. [
DOI:10.1517/14656561003601994]
48. Dreer LE, Girkin C, Mansberger SL. Determinants of Medication Adherence to Topical Glaucoma Therapy. J Glaucoma 2012; 21(4): 234. [
DOI:10.1097/IJG.0b013e31821dac86]
49. Bour T, Blanchard F, Segal A. Therapeutic Observance and Life of Patients with Primary Open-angle Glaucoma. Apropos of 341 Cases in the Department of Marne. J Fr Ophtalmol 1993; 16(6-7): 380-91.
50. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for Glaucoma: Adherence by the Elderly. Am J Public Health 1993; 83(5): 711-6. [
DOI:10.2105/AJPH.83.5.711]
51. Kholdebarin R, Campbell RJ, Jin YP, et al. Multicenter Study of Compliance and Drop Administration in Glaucoma. Can J Ophthalmol 2008; 43:454-61. [
DOI:10.3129/i08-076]
52. Boland MV, Chang DS, Frazier T, et al. Electronic Monitoring To Assess Adherence With Once - Daily Glaucoma Medications And Risk Factors For Nonadherence: The Automated Dosing Reminder Study. JAMA Ophthalmol 2014; 132(7): 838-44. [
DOI:10.1001/jamaophthalmol.2014.856]
53. Welge-Lussen U, Weis S, Yu AL. Assessing the Adherence Behavior of Glaucoma Patients to Topical Eye Drops. Patient Prefer Adherence 2015; 18:17-23. [
DOI:10.2147/PPA.S69943]
54. Mehari T, Giorgis AT, Shibeshi W. Level of Adherence to ocular Hypotensive Agents and its Determinant Factors Among Glaucoma Patients in Menelik II Referral Hospital, Ethiopia. BMC Ophthalmol 2016; 16(1): 131. [
DOI:10.1186/s12886-016-0316-z]
55. Granström PA. Progression of Visual Field Defects in Glaucoma: Relation to compliance with Pilocarpine Therapy. Arch Ophthalmol 1985; 103(4): 529-31. [
DOI:10.1001/archopht.1985.01050040071020]
56. Granström PA, Norell S. Visual Ability and Drug Regimen: Relation to Compliance with Glaucoma Therapy. Acta Ophthalmol 1983; 61(2): 206-19. [
DOI:10.1111/j.1755-3768.1983.tb01414.x]
57. Kharod BV, Johnson PB, Nesti HA, et al. Effect Of Written Instructions On Accuracy Of Self-Reporting Medication Regimen In Glaucoma Patients. J Glaucoma 2006; 15(3): 244-7. [
DOI:10.1097/01.ijg.0000212213.18018.8f]
58. Tse AP, Shah M, Jamal N, et al. Glaucoma Treatment Adherence at a United Kingdom General Practice. Eye 2016; 30(8): 1118. [
DOI:10.1038/eye.2016.103]
59. Sayner R, Carpenter DM, Blalock SJ, et al. Accuracy of Patient-Reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared wit3244h Electronic Monitors. Clin Ther 2015; 37(9): 1975-85. [
DOI:10.1016/j.clinthera.2015.06.008]